4-1BB signaling synergizes with programmed death ligand 1 blockade to augment CD8 T cell responses during chronic viral infection

Vaiva Vezys, Pablo Penaloza-Macmaster, Daniel L. Barber, Sang Jun Ha, Bogumila Konieczny, Gordon J. Freeman, Robert S. Mittler, Rafi Ahmed

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Previous studies have identified the inhibitory role that the programmed death 1 (PD-1) pathway plays during chronic infection. Blockade of this pathway results in rescue of viral-specific CD8 T cells, as well as reduction of viral loads in mice chronically infected with lymphocytic choriomeningitis virus (LCMV). We tested the effect of combining PD ligand 1 (PD-L1) blockade with an agonistic regimen that induces 4-1BB costimulation during chronic LCMV infection. There is a boosting effect in the rescue of LCMV-specific CD8 T cell responses after dual treatment with PD-L1 blockade and 4-1BB agonistic Abs when the amount and timing of 4-1BB costimulation are carefully controlled. When PD-L1-blocking Abs are given together with a single low dose of anti-4-1BB agonistic Abs, there is an enhanced and stable expansion of viral-specific CD8 T cells. Conversely, when blocking Abs to PD-L1 are given with a repetitive high dose of anti-4-1BB, there is an initial synergistic expansion of viral-specific CD8 T cells by day 7, followed by dramatic apoptosis by day 14. Viral control paralleled CD8 T cell kinetics after dual treatment. By day 7 posttreatment, viral titers were lower in both of the combined regimens (compared with PD-L1 blockade alone). However, whereas the high dose of anti-4-1BB plus PD-L1 blockade resulted in rebound of viral titers to original levels, the low dose of anti-4-1BB plus PD-L1 blockade resulted in a stable reduction of viral loads. These findings demonstrate the importance of carefully manipulating the balance between activating and inhibitory signals to enhance T cell responses during chronic infection.

Original languageEnglish
Pages (from-to)1634-1642
Number of pages9
JournalJournal of Immunology
Volume187
Issue number4
DOIs
Publication statusPublished - 2011 Aug 15

Fingerprint

Virus Diseases
Ligands
T-Lymphocytes
Lymphocytic choriomeningitis virus
Viral Load
Infection
Apoptosis

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this

Vezys, Vaiva ; Penaloza-Macmaster, Pablo ; Barber, Daniel L. ; Ha, Sang Jun ; Konieczny, Bogumila ; Freeman, Gordon J. ; Mittler, Robert S. ; Ahmed, Rafi. / 4-1BB signaling synergizes with programmed death ligand 1 blockade to augment CD8 T cell responses during chronic viral infection. In: Journal of Immunology. 2011 ; Vol. 187, No. 4. pp. 1634-1642.
@article{c011a52fcba04b0188884cbd0a9a7a74,
title = "4-1BB signaling synergizes with programmed death ligand 1 blockade to augment CD8 T cell responses during chronic viral infection",
abstract = "Previous studies have identified the inhibitory role that the programmed death 1 (PD-1) pathway plays during chronic infection. Blockade of this pathway results in rescue of viral-specific CD8 T cells, as well as reduction of viral loads in mice chronically infected with lymphocytic choriomeningitis virus (LCMV). We tested the effect of combining PD ligand 1 (PD-L1) blockade with an agonistic regimen that induces 4-1BB costimulation during chronic LCMV infection. There is a boosting effect in the rescue of LCMV-specific CD8 T cell responses after dual treatment with PD-L1 blockade and 4-1BB agonistic Abs when the amount and timing of 4-1BB costimulation are carefully controlled. When PD-L1-blocking Abs are given together with a single low dose of anti-4-1BB agonistic Abs, there is an enhanced and stable expansion of viral-specific CD8 T cells. Conversely, when blocking Abs to PD-L1 are given with a repetitive high dose of anti-4-1BB, there is an initial synergistic expansion of viral-specific CD8 T cells by day 7, followed by dramatic apoptosis by day 14. Viral control paralleled CD8 T cell kinetics after dual treatment. By day 7 posttreatment, viral titers were lower in both of the combined regimens (compared with PD-L1 blockade alone). However, whereas the high dose of anti-4-1BB plus PD-L1 blockade resulted in rebound of viral titers to original levels, the low dose of anti-4-1BB plus PD-L1 blockade resulted in a stable reduction of viral loads. These findings demonstrate the importance of carefully manipulating the balance between activating and inhibitory signals to enhance T cell responses during chronic infection.",
author = "Vaiva Vezys and Pablo Penaloza-Macmaster and Barber, {Daniel L.} and Ha, {Sang Jun} and Bogumila Konieczny and Freeman, {Gordon J.} and Mittler, {Robert S.} and Rafi Ahmed",
year = "2011",
month = "8",
day = "15",
doi = "10.4049/jimmunol.1100077",
language = "English",
volume = "187",
pages = "1634--1642",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "4",

}

Vezys, V, Penaloza-Macmaster, P, Barber, DL, Ha, SJ, Konieczny, B, Freeman, GJ, Mittler, RS & Ahmed, R 2011, '4-1BB signaling synergizes with programmed death ligand 1 blockade to augment CD8 T cell responses during chronic viral infection', Journal of Immunology, vol. 187, no. 4, pp. 1634-1642. https://doi.org/10.4049/jimmunol.1100077

4-1BB signaling synergizes with programmed death ligand 1 blockade to augment CD8 T cell responses during chronic viral infection. / Vezys, Vaiva; Penaloza-Macmaster, Pablo; Barber, Daniel L.; Ha, Sang Jun; Konieczny, Bogumila; Freeman, Gordon J.; Mittler, Robert S.; Ahmed, Rafi.

In: Journal of Immunology, Vol. 187, No. 4, 15.08.2011, p. 1634-1642.

Research output: Contribution to journalArticle

TY - JOUR

T1 - 4-1BB signaling synergizes with programmed death ligand 1 blockade to augment CD8 T cell responses during chronic viral infection

AU - Vezys, Vaiva

AU - Penaloza-Macmaster, Pablo

AU - Barber, Daniel L.

AU - Ha, Sang Jun

AU - Konieczny, Bogumila

AU - Freeman, Gordon J.

AU - Mittler, Robert S.

AU - Ahmed, Rafi

PY - 2011/8/15

Y1 - 2011/8/15

N2 - Previous studies have identified the inhibitory role that the programmed death 1 (PD-1) pathway plays during chronic infection. Blockade of this pathway results in rescue of viral-specific CD8 T cells, as well as reduction of viral loads in mice chronically infected with lymphocytic choriomeningitis virus (LCMV). We tested the effect of combining PD ligand 1 (PD-L1) blockade with an agonistic regimen that induces 4-1BB costimulation during chronic LCMV infection. There is a boosting effect in the rescue of LCMV-specific CD8 T cell responses after dual treatment with PD-L1 blockade and 4-1BB agonistic Abs when the amount and timing of 4-1BB costimulation are carefully controlled. When PD-L1-blocking Abs are given together with a single low dose of anti-4-1BB agonistic Abs, there is an enhanced and stable expansion of viral-specific CD8 T cells. Conversely, when blocking Abs to PD-L1 are given with a repetitive high dose of anti-4-1BB, there is an initial synergistic expansion of viral-specific CD8 T cells by day 7, followed by dramatic apoptosis by day 14. Viral control paralleled CD8 T cell kinetics after dual treatment. By day 7 posttreatment, viral titers were lower in both of the combined regimens (compared with PD-L1 blockade alone). However, whereas the high dose of anti-4-1BB plus PD-L1 blockade resulted in rebound of viral titers to original levels, the low dose of anti-4-1BB plus PD-L1 blockade resulted in a stable reduction of viral loads. These findings demonstrate the importance of carefully manipulating the balance between activating and inhibitory signals to enhance T cell responses during chronic infection.

AB - Previous studies have identified the inhibitory role that the programmed death 1 (PD-1) pathway plays during chronic infection. Blockade of this pathway results in rescue of viral-specific CD8 T cells, as well as reduction of viral loads in mice chronically infected with lymphocytic choriomeningitis virus (LCMV). We tested the effect of combining PD ligand 1 (PD-L1) blockade with an agonistic regimen that induces 4-1BB costimulation during chronic LCMV infection. There is a boosting effect in the rescue of LCMV-specific CD8 T cell responses after dual treatment with PD-L1 blockade and 4-1BB agonistic Abs when the amount and timing of 4-1BB costimulation are carefully controlled. When PD-L1-blocking Abs are given together with a single low dose of anti-4-1BB agonistic Abs, there is an enhanced and stable expansion of viral-specific CD8 T cells. Conversely, when blocking Abs to PD-L1 are given with a repetitive high dose of anti-4-1BB, there is an initial synergistic expansion of viral-specific CD8 T cells by day 7, followed by dramatic apoptosis by day 14. Viral control paralleled CD8 T cell kinetics after dual treatment. By day 7 posttreatment, viral titers were lower in both of the combined regimens (compared with PD-L1 blockade alone). However, whereas the high dose of anti-4-1BB plus PD-L1 blockade resulted in rebound of viral titers to original levels, the low dose of anti-4-1BB plus PD-L1 blockade resulted in a stable reduction of viral loads. These findings demonstrate the importance of carefully manipulating the balance between activating and inhibitory signals to enhance T cell responses during chronic infection.

UR - http://www.scopus.com/inward/record.url?scp=80051925716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051925716&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.1100077

DO - 10.4049/jimmunol.1100077

M3 - Article

C2 - 21742975

AN - SCOPUS:80051925716

VL - 187

SP - 1634

EP - 1642

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 4

ER -